Brian Petullo1, Lai Wei1, Melissa Yereb1, Alison Neal1, Jeffrey Rose1, Tanios Bekaii-Saab1, Christina Wu1. 1. 1 Wexner Medical Center, 2 Center for Biostatistics, Comprehensive Cancer Center, 3 Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
Abstract
BACKGROUND: The appropriate second-line therapy for patients with advanced gastroesophageal (GE) or esophageal (E) cancer after failure of first-line platinum-based therapy is unclear. Pralatrexate and docetaxel have independently been shown to have efficacy in the treatment of these cancers. Thus, we performed a clinical trial examining the efficacy of the combination of these agents in the treatment of GE and E cancer. METHODS: A Fleming phase II design with a single stage of 32 patients was planned. Pralatrexate 120 mg/m(2) and docetaxel 35 mg/m(2) were administered on day 1 of 14-day cycles. The primary end-point was to evaluate the overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and secondary end-points were to evaluate for progression-free survival (PFS) and overall survival (OS). RESULTS: The study was halted prematurely due to loss of funding after the accrual of six patients. Two patients had stable disease (SD) and four patients had disease progression per RECIST. When applying PERCIST criteria in four evaluable patients, two had a partial response (PR) and two had SD. Median PFS was 1.9 months (95% CI, 0.8-7.2) and median OS was 5.5 (0.8-11.7) months. CONCLUSIONS: Pralatrexate and docetaxel as therapy in refractory esophageal and GE adenocarcinoma did not demonstrate meaningful preliminary activity. PERCIST may prove to better assess the meaningfulness of anatomic SD.
BACKGROUND: The appropriate second-line therapy for patients with advanced gastroesophageal (GE) or esophageal (E) cancer after failure of first-line platinum-based therapy is unclear. Pralatrexate and docetaxel have independently been shown to have efficacy in the treatment of these cancers. Thus, we performed a clinical trial examining the efficacy of the combination of these agents in the treatment of GE and E cancer. METHODS: A Fleming phase II design with a single stage of 32 patients was planned. Pralatrexate 120 mg/m(2) and docetaxel 35 mg/m(2) were administered on day 1 of 14-day cycles. The primary end-point was to evaluate the overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and secondary end-points were to evaluate for progression-free survival (PFS) and overall survival (OS). RESULTS: The study was halted prematurely due to loss of funding after the accrual of six patients. Two patients had stable disease (SD) and four patients had disease progression per RECIST. When applying PERCIST criteria in four evaluable patients, two had a partial response (PR) and two had SD. Median PFS was 1.9 months (95% CI, 0.8-7.2) and median OS was 5.5 (0.8-11.7) months. CONCLUSIONS:Pralatrexate and docetaxel as therapy in refractory esophageal and GE adenocarcinoma did not demonstrate meaningful preliminary activity. PERCIST may prove to better assess the meaningfulness of anatomic SD.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Jaffer A Ajani; Miguel B Fodor; Sergei A Tjulandin; Vladimir M Moiseyenko; Yee Chao; Sebastiao Cabral Filho; Alejandro Majlis; Sylvie Assadourian; Eric Van Cutsem Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: Hugo E R Ford; Andrea Marshall; John A Bridgewater; Tobias Janowitz; Fareeda Y Coxon; Jonathan Wadsley; Wasat Mansoor; David Fyfe; Srinivasan Madhusudan; Gary W Middleton; Daniel Swinson; Stephen Falk; Ian Chau; David Cunningham; Paula Kareclas; Natalie Cook; Jane M Blazeby; Janet A Dunn Journal: Lancet Oncol Date: 2013-12-10 Impact factor: 41.316
Authors: J A Wils; H O Klein; D J Wagener; H Bleiberg; H Reis; F Korsten; T Conroy; M Fickers; S Leyvraz; M Buyse Journal: J Clin Oncol Date: 1991-05 Impact factor: 44.544
Authors: Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani Journal: J Clin Oncol Date: 2006-11-01 Impact factor: 44.544
Authors: Christopher G Azzoli; Lee M Krug; Jorge Gomez; Vincent A Miller; Mark G Kris; Michelle S Ginsberg; Roxanne Henry; Jessica Jones; Leslie Tyson; Megan Dunne; Barbara Pizzo; Amy Farmer; Ennapadam Venkatraman; Robert Steffen; F M Sirotnak Journal: Clin Cancer Res Date: 2007-05-01 Impact factor: 12.531
Authors: David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman Journal: N Engl J Med Date: 2008-01-03 Impact factor: 91.245